ABSTRACT. Background. Iron-fortified formulas are recommended throughout infancy and are frequently used beyond, yet safety aspects have been inadequately studied. Iron could theoretically increase pro-oxidant stress, with potential adverse effects, including infection risk, and some clinicians suspect that iron-fortified formulas induce gastrointestinal disturbance.
T he American Academy of Pediatrics recommends that infants up to 1 year old who are not being breastfed should be given iron-fortified formulas rather than cow's milk. 1 The use of such formulas reduces the high frequency of iron deficiency anemia in infants 2 and in consequence may benefit their long-term cognitive development, 3 although this is now debated. 4, 5 A high prevalence of iron deficiency (particularly in some populations 6 has raised the possibility that moderately low iron stores in early life are physiologic rather than pathologic. [7] [8] [9] Indeed, theoretical concerns 10 have made some clinicians cautious in their use of iron-fortified formulas. 9, 11 By increasing oxidant stress 10 and providing iron for microorganisms, high levels of body iron may predispose to infections in adults, 12, 13 increase mortality in kwashiorkor, 10, 14 and theoretically increase the risk of asthma. 15 Parenteral iron supplementation may increase the risk of sepsis, 16 malaria, 17 and respiratory infections 18 in infants; and oral iron supplementation has been associated with growth retardation 19 and changes in gastrointestinal flora in children, 20 and an increased incidence of malaria 12 and amoebiasis 21 in adults. There is also a prevalent view in the United States that infants fed iron-fortified formulas may develop gastrointestinal problems and this belief has encouraged the continued use and manufacture of low iron formulas 11 (recently discussed by Ryan 22 ). However, the potential adverse effects of iron-fortified formulas consumed by infants in industrialized countries have not been adequately investigated.
Data suggesting a lack of adverse health outcomes with iron-fortified formulas have been based on epidemiologic studies, 23, 24 randomized trials of insufficient power to detect infrequent adverse clinical events, [25] [26] [27] [28] [29] [30] [31] or studies in developing countries 27, 32 where a greater prevalence and severity of iron deficiency may reduce potential adverse effects of iron supplementation. Many studies have targeted nutritionally vulnerable populations 23, 27, 29, [31] [32] [33] and the risks of iron supplementation for the majority of infants who are iron replete are uncertain. Furthermore, few studies have focused on follow-on formulas that are marketed in Europe and a number of countries for consumption by infants over 6 months old 31, 33, 34 and may have higher iron concentrations (eg, 12 mg/L) than formulas used for younger children (eg, 6.5 mg/L). 31 Therefore, we tested the hypothesis that the incidence of infections (principal outcome), gastrointestinal symptoms, and risk of asthma was greater in infants randomized to high iron-fortified formula (12 mg/L iron), than those randomized to an otherwise identical but low iron formula (.9 mg/L) or to pasteurized whole cow's milk. Randomization of infants to cow's milk was ethical because nutritional intervention was confined to infants already on cow's milk and at the time of the study the UK Department of Health accepted the use of cow's milk in infants over 6 months old.
METHODS

Subjects
Letters were sent to the parents of potential subjects approaching 9 months old identified from birth registers at the 3 collaborating centers in the United Kingdom (Leicester, Nottingham, and Norwich). If mothers reported that their infant was receiving only cow's milk and no formula, they were sent a second letter with information about the trial. Mothers agreeing to participate were visited at home by a trained research nurse who obtained informed, written consent. The study was approved by the human research ethics committee at each of the collaborating centers.
Healthy infants from singleton pregnancies (or sole survivors of multiple pregnancies) over 36 weeks' gestation with birth weight over 2.5 kg were eligible. Infants with severe chronic disease, congenital anomalies, hematologic disorders, evidence of developmental delay, or other conditions known to affect growth and development were excluded as were those receiving or having previously received iron supplements or blood transfusions. Infants meeting the eligibility criteria, whose parents consented, were randomized from opaque sealed envelopes to: 1) cow's milk (defined as whole, pasteurized fresh milk without added vitamins or minerals, excluding skimmed or semiskimmed milk, and estimated to contain .5 mg/L of iron); 2) iron-fortified formula (containing 12 mg/L iron as ferrous sulfate); or 3) an otherwise identical specially manufactured unfortified formula containing .9 mg/L of iron. Children from Asian families (who are at higher risk for iron deficiency) 6 were separately randomized to ensure balance among groups (only 10 were recruited).
The nutrient composition of the infant formula supplied by Wyeth Laboratories, Maidenhead, United Kingdom is given in Table 1 . Solid foods were not restricted, and mothers of infants in the formula groups were asked not to give additional vitamins or mineral supplements. Other than iron contained in the mixed diets of infants, no other sources of iron were given. All infants, mothers, and investigators were blinded to the 2 formulas.
Sample Size
In a previous study, 27 the standard deviation (SD) of the number of infections per child per year (from 3 to 12 months old, which overlaps with the age range selected by us) in infants fed either iron-fortified or unfortified formula was ϳ3. Therefore, to detect a difference of 1 infection between infants receiving a high or low iron formula with 80% power and 5% significance required ϳ144 subjects in each formula group. 35 
Study Procedures
All participating infants were seen at recruitment at 9 months old and again at 12, 15, and 18 months old. At randomization, a clinical and feeding history, and demographic, social class, and maternal educational attainment data were obtained. Social class was based on the occupation of the parent providing the primary financial support for the family or if both parents worked the father's occupation. The clinical history, repeated at each follow-up visit, specifically included a history of infective episodes, diagnosis of atopic conditions, bowel habits, and stool characteristics, medications given, and any negative events experienced by the infant (such as allergy, rash, or acute illness), during the previous 3 months. The problems of maternal recall of illness are recognized, but because the same data collection methods were used for all 3 dietary groups, comparison among groups may be valid.
At the target ages, naked weight was measured accurate to .1 kg (Seca digital baby scales) using standard protocols and by research nurses trained in the techniques involved. Dietary intake was assessed at 9, 12, and 15 months old by a 2-day dietary dairy kept by the mother and development assessed at 18 months old using the motor and mental scales of the Bayley Scales of Infant Development II. Growth and development data (the principal efficacy outcomes) are reported elsewhere, 5 and the number of infections (the principal safety outcome) and other clinical safety data are reported here.
Clinical Events
Maternal reports of the 3 most common infective events in infancy, namely upper respiratory tract infections, chest infections treated with antibiotics, and episodes of diarrhea or vomiting, were recorded at each follow-up visit and the sum of these events per infant taken as an index of morbidity attributable to infection. Any more serious infections were recorded separately. Diarrhea was defined as an increase in stool frequency and loose stools (according to the mother), with the illness episode lasting longer than 24 hours, and vomiting excluded possetting or regurgitation. An index of general morbidity was also obtained from the number of consultations with the family doctor and the number of hospital admissions (defined as at least an overnight stay in hospital). A diagnosis of asthma or eczema (made by the family doctor or pediatrician) and a history of wheeze were also recorded. Other details reported by the mother included the normal stool frequency per week, and normal stool consistency (watery, runny, mushy but formed, soft but formed, or hard) 36 and history of constipation, blood in the stool and use of laxatives in the preceding 3 months.
Hematology
Blood was obtained by venepuncture (and occasionally if this was unsuccessful from a heel prick) from infants 18 months old. Hemoglobin, serum ferritin, and serum transferrin receptor concentrations were determined at the end of the study in samples stored at Ϫ18°C, and all analyses were conducted at the Institute of Food Research, Norwich, UK. Ferritin concentrations were measured using an in house enzyme-linked immunoadsorbent assay and an international ferritin standard (National Institute of Biological Standards and Control, NIBSC, Potters Bar, Hertfordshire, UK) and plasma transferrin receptor concentration using a com- mercial enzyme-linked immunoadsorbent assay system (R&D Systems, Abingdon, UK).
Statistical Analysis
A 1-way analysis of covariance was used to detect statistically significant differences in normally distributed variables among the 3 randomized groups with statistical significance defined as P Ͻ .05. If an intergroup difference was identified by this technique, Student's t test was used to compare means between 2 groups with Bonferroni's P corrections applied to maintain ␣ at .05. The Kruskal-Wallis test was used to detect statistically significant differences in nonparametric variables and the 2 test was used to compare the proportions of infants with categorical clinical events or diagnoses. All analyses were conducted and presented on an intention to treat basis, with the denominator for analysis of categorical variables as the number of infants in each dietary group at randomization. Regression analyses were used to adjust associations between formula type and outcome variable for possible confounding factors (gender, birth weight, duration of breastfeeding, maternal education, and social class) and for the number of 3-month follow-up visits attended as part of the trial protocol (maximum ϭ 3).
RESULTS
Compliance
Initial letters were sent to 11 021 mothers of whom 2043 (19%) replied. Of the mothers replying 592 (29%) were already feeding their infants cow's milk and of these 493/592 (83%) agreed to take part in this study.
The number of infants fed the assigned diet for Ͻ6 months was similar for the iron-fortified (n ϭ 36/ 162; 22%) and unfortified groups (n ϭ 38/165; 23%) and greater than for subjects fed cow's milk (n ϭ 7/166; 4%). Of mothers who stopped the assigned diet before 6 months, a significantly higher proportion refused assessment at 18 months old (51/81, 63%) compared with those who complied (14/412; 3%).
At 18 months old, 160 (96%) of infants fed cow's milk, 135 (82%) fed unfortified formula, and 133 (82%) receiving iron-fortified formula were seen. Subjects not complying were more likely to have mothers with no educational qualifications (26% vs 13%; P ϭ .003), come from a lower social class family (67% vs 55%; P ϭ .058), and to be significantly lighter at 9 months old (9.0 vs 9.3 kg; P ϭ .05).
Energy intake from the assigned milk was similar for the 3 dietary groups at 9 months old (mean, SD: 
Hematology
Blood samples were analyzed for hemoglobin, serum ferritin, and transferrin receptor concentrations after sample subdivision. An unfortunate technical problem resulted in occasional anomalous results for hemoglobin values. Therefore, for this study, we have elected not to include any hemoglobin data, particularly because, as shown below, none of the subjects had significant iron deficiency as evidenced by the serum transferrin receptor concentration results.
At 18 months old, the geometric mean serum ferritin concentrations of children fed iron-fortified formula (21.4, log SD: .22 g/L; n ϭ 93) was significantly greater than children receiving control formula (13.3, .24 g/L; n ϭ 81; P Ͻ .001) or cow's milk (14.3, .28 g/L; n ϭ 96; P Ͻ .001). Taking the normal lower range for serum ferritin as 8 g/L, 31 fewer infants receiving iron-fortified formula (4/93; 4.3%) had low iron stores than infants receiving low iron formula (13/81; 16%; P ϭ .009) or cow's milk (17/96; 17.8%; P ϭ .003).
Mean (SD) serum transferrin receptor levels did not differ in the 3 dietary groups (iron-fortified formula: 2. 
Morbidity
No clinical events or serious infections were observed. There were no significant differences in demographic details, feeding histories (Table 2) , or preintervention morbidity (Table 3) in children randomized to the 3 milk groups. By 18 months old, the incidence of asthma, eczema, chest infections, diarrhea and vomiting, and attained weight did not differ statistically in children receiving iron-fortified or unfortified formula or cow's milk (Table 3) . Nei- ther the total number of consultations with the family doctor nor the number of infective episodes per child over 9 months (colds, chest infections, and episodes of diarrhea or vomiting) were significantly different in the 3 dietary groups (Table 3) .
Bowel Habits and Stool Characteristics
There were no statistically significant differences in the number of children with a history of constipation, laxative use, blood in the stool, or hard or loose (runny or watery) stool consistency in the 3 dietary groups between 9 and 18 months old (Table 4) . By chance, the stool frequency at randomization was higher in children randomized to cow's milk than those receiving low or high iron containing formulas, but this difference was no longer apparent at 18 months old.
After adjusting for possible confounding factors (gender, birth weight, duration of breastfeeding, maternal education, social class, and the number of 3 Total infective episodes ϭ upper respiratory tract infections ϩ diarrhea and/or vomiting ϩ chest infections. n ϭ number with data. Analysis on an intention-to-treat basis using * test (with denominator as the number in each dietary group at randomization); †Kruskal-Wallis test; ‡1-way analysis of variance. §Proportions with data to 18 months old. Analysis on an intention to treat basis using * 2 test (with denominator as the number in each dietary group at randomization); and †1-way analysis of variance.
‡ Proportions with data to 18 months old. n indicates number with data.
monthly follow-up visits attended) using multiple regression analyses, associations between dietary group and outcome variable (morbidity, bowel habits, or stool characteristics at 18 months old) remained nonsignificant (results not presented). Analyses were also repeated on a nonintention-to-treat basis, after restricting the data to subjects with complete follow-up, and showed no significant associations between diet and outcome variables (data not presented).
DISCUSSION
Iron deficiency is arguably the most common nutritional deficiency in the developed world. 6 Infants in the second 6 months of life are particuarly vulnerable and in Europe, follow-on formulas with higher iron concentrations than standard formulas have been specifically developed to enhance iron intake after 6 months old. 6 The use of iron-fortified formulas in the second 6 months of life has been approved by the European Society for Pediatric Gastroenterology 38 and their increased consumption is likely to have contributed to the dramatically reduced incidence of iron deficiency in the United States.
2 However, although heavily promoted and widely used, there are few data to support the safety of ironfortified formulas, particularly in iron-replete infants.
The present study found no statistically significant differences in the frequency of adverse events, infections, or general morbidity in infants fed iron-fortified or unfortified formula. Consistent with previous reports, 24 -29 stool frequency and character and the incidence of gastrointestinal symptoms also did not differ among dietary groups suggesting that the consumption of iron-fortified formula was not associated with constipation or diarrhea at least in this age group. We would emphasize, therefore, that the common belief that iron-fortified formulas make infants constipated (a belief that may result in inappropriate use of low-iron formulas) is not supported by our study. However, on occasion, iron-fortified formulas have been associated with changes in stool flora, 20 color, or consistency 30 in younger infants; and perhaps with illness in a nonrandomized study from a tropical country. 39 As expected, mean plasma ferritin concentrations at 18 months old were significantly higher in infants fed iron-fortified rather than standard infant formula or cow's milk and levels were similar to a recent study of inner city infants. 31 However, most infants not receiving iron-fortified formula also had adequate iron stores (consistent with an adequate iron intake from dietary sources other than formula), and infants on cow's milk had similar iron stores to those on low iron formula despite evidence of occult fecal blood loss in studies of younger infants on cow's milk. Furthermore, all children with hematologic data had serum transferrin receptor concentrations Ͻ6.5 mg/L (a suggested upper limit of normal with higher concentrations indicating iron deficiency in older infants). 37 Therefore, although low ferritin concentrations indicated depletion of iron stores in some, no child with hematologic data had evidence of a significant iron deficiency. 37 Few studies have adequately assessed the safety of iron-fortified formulas particularly in populations with a low incidence of iron deficiency. In an early trial of 1048 infants, significantly fewer infections occurred in iron-supplemented children, 23 but unfortunately this study was not randomized or analyzed on an intention-to-treat basis. More recent epidemiologic studies 24 or randomized trials 34 have not shown an increased risk of infection with iron supplementation, although many had methodological problems such as a high drop-out rate, 28 ,29 short follow-up (Ͻ3 months), 25, 30 or lack of a control group simultaneously fed an otherwise identical but low iron formula. 31, 33 Two trials (comparing formula with iron concentrations of 58 vs 12 mg/L 27 and 12.7 vs 7.4 mg/L 28 ) were difficult to interpret because both index and control subjects received iron-fortified formula. Furthermore, of the studies from developed countries specifically investigating iron-fortified formulas containing 12 mg/L iron in infants over 6 months old, 2 had a cow's milk control group, 31,33 1 did not report the incidence of adverse clinical events, 40 and 1 had unequal numbers in the index and control groups and did not include morbidity data in the statistical analyses. 34 Nevertheless, a similar infection rate in the present study among infants given formulas containing 12 mg/L or low iron formula was consistent with published data, 29 and with the hypothesis that most adverse effects of iron supplementation are seen in areas where malaria is endemic and rarely in infancy. 22, 32 The longer term risks of iron supplementation in iron-replete populations are uncertain. Theoretical considerations of the role of iron as a pro-oxidant 10 and possible benefits of lower iron stores 7, 8 have raised concerns about potential harmful effects of indiscriminate widespread iron supplementation. 9 However, although there are limited long-term data, few harmful clinical consequences of oral iron supplementation in infancy have been described, and in contrast to previous data, 19 we found no adverse effects of iron supplementation on the weight gain of iron-replete infants.
We believe that the present study is the largest randomized, double-blind trial comparing an ironfortified formula with an identical formula with low iron concentration. Our data are likely to be applicable to infants in the second 6 months of life because this age overlaps with the age range in the present study. Although the sample size was sufficient to detect a statistically significant difference of 1 infection over the study period, we found no difference in infection rates or any other aspect of morbidity or stool characteristics among groups. Thus, in terms of the range of outcomes explored in this study, we did not find that consumption of a high iron-containing formula (12 mg/L) was associated with adverse health outcomes in older infants and toddlers.
